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Abstract
The detection of antisense RNA is hampered by reverse transcription (RT) non-specific priming, due to the ability of RNA
secondary structures to prime RT in the absence of specific primers. The detection of antisense RNA by conventional RT-PCR
does not allow assessment of the polarity of the initial RNA template, causing the amplification of non-specific cDNAs. In this
study we have developed a modified protocol for the detection of human immunodeficiency virus type 1 (HIV-1) antisense
protein (ASP) RNA. Using this approach, we have identified ASP transcripts in CD4+ T cells isolated from five HIV-infected
individuals, either untreated or under suppressive therapy. We show that ASP RNA can be detected in stimulated CD4+
T cells from both groups of patients, but not in unstimulated cells. We also show that in untreated patients, the patterns of
expression of ASP and env are very similar, with the levels of ASP RNA being markedly lower than those of env. Treatment
of cells from one viraemic patient with a-amanitin greatly reduces the rate of ASP RNA synthesis, suggesting that it is
associated with RNA polymerase II, the central enzyme in the transcription of protein-coding genes. Our data represent the
first nucleotide sequences obtained in patients for ASP, demonstrating that its transcription indeed occurs in those HIV-1
lineages in which the ASP open reading frame is present.
INTRODUCTION
The ASP gene is an antisense open reading frame (ORF)
potentially encoding for the putative HIV-1 antisense pro-
tein (ASP) [1]. In retroviruses, antisense transcripts coding
for proteins have been characterized for each member of the
human T-cell leukaemia virus (HTLV) family (reviewed in
[2]). In HTLV-1, antisense transcription results in the pro-
duction of HTLV-1 basic zipper protein (hbz), which is
involved in the regulation of adult T-cell leukaemia onco-
genesis and whose highly conserved ORF is located between
the env and tax/rex genes [3, 4]. An antisense protein called
Aph-2 has also been found in HTLV-2 [5], and is seemingly
implicated in the regulation of viral transcription and trans-
lation. Antisense proteins Aph-3 and Aph-4 have been also
described in the regulation of HTLV-3 and HTLV-4 tran-
scription [6–8].
In HIV-1, the ASP ORF is located in the envelope gene at
the junction between gp120 and gp41, in the antisense read-
ing frame  2, in a similar position to the hbz of HTLV-1
[1]. In HXB2, the reference sequence for subtype B, the ASP
ORF is 570 bp long, spanning coordinates 7942–7373 [9]. A
study on almost 23 000 HIV genomes showed the preva-
lence of the ASP ORF in the large majority of group M. In
subtype B it has been recognized in 85% of the genomes
[10]. The putative ASP protein is 189 amino acids long and
appears to have two potential transmembrane helices with a
cytoplasmic N-terminus, indicating that it could be associ-
ated with cell membranes [1, 11, 12].
Although the ASP ORF was first discovered three decades
ago, the existence of its gene product in HIV-1 infection is
still controversial. Some authors support the hypothesis of
ASP being part of a long non-coding (lnc) RNA with
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Fig. 1. Phylogenetic tree showing the alignment of the ASP and env sequences obtained in our patients with the reference sequences
of the HIV-1 M group subtypes. The tree was inferred using the maximum-likelihood method with 1000 bootstrap replicates using MEGA
7.0 software. ASP sequences obtained in cells were converted to the env reverse and complementary orientation and reading frame,
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regulatory functions [13, 14], whereas others argue that it
might be a protein involved in ASP-induced autophagy to
improve virion production [15]. Regardless of its real
nature, bioinformatic data demonstrate that ASP, either as
regulatory RNA or protein (or both?), is very likely to play a
function in HIV pathogenesis, since the degree of conserva-
tion of its ORF in subtype B is higher than would be
expected if it had no function at all [10]. In contrast, the
lack of a good ASP ORF in many HIV-1 lineages points to
this function not being crucial for survival, or at least not
yet [10]. Although several studies indicate that the ASP
gene does indeed give rise to several transcripts of different
lengths in HIV in vitro [9, 16], no information is currently
available about the existence of a translation product in
HIV-infected individuals. The nucleotide sequence of ASP
transcripts in infected individuals is still missing and in fact
the bioinformatic data supporting the distribution of the
ASP ORF in the various subtypes do not come from actual
ASP RNA sequences, but have been extrapolated from enve-
lope web alignments, codon-aligned in the ASP antisense
reading frame (https://www.hiv.lanl.gov/content/sequence/
HIV/SI_alignments/ASP.html) [10].
The main difficulty in detecting ASP RNA transcripts lies in
their complementarity to env RNA sequences that are also
present in infected cells. The most sensitive and specific
approach for the detection of RNA transcripts is RT-PCR,
with the use of the gene-specific antisense primer to prime
the reaction of reverse transcription (RT) in order to syn-
thesize the cDNA of the right polarity. In recent years a phe-
nomenon called RT self-priming (or endogenous priming)
has been observed, whereby non-specific priming of the
reaction of RT occurs due to the ability of some RNA sec-
ondary structures, such as RNA hairpins or loops, to prime
RT even in the absence of primers [17]. Since these struc-
tures are able to prime RT in both directions, it is not possi-
ble to assess the polarity of the initial RNA template from
which the products of subsequent PCR amplifications are
generated. Thus, common RT-PCR protocols, which are
routinely used for sense RNA detection, are unable to
provide reliable information when applied to the study of
antisense transcription.
In this study we have developed a novel approach to detect-
ing ASP RNA based on a modification of the protocol
described by Haist and coworkers [17], whereby the ASP-
specific antisense primer is biotynylated and the resulting
cDNA affinity-purified in order to eliminate non-specific
products. Our goals were (i) to demonstrate that the ASP
ORF is expressed during HIV infection and (ii) to isolate
and sequence ASP RNA from patients. Our results show
that ASP transcripts are easily detectable in stimulated
CD4+ T cells isolated from untreated patients and, to a
lesser extent, from patients undergoing antiretroviral ther-
apy (ART). Our data also represent the first nucleotide
sequences obtained in patients for ASP transcription prod-
ucts, demonstrating that ASP is indeed expressed in those
HIV-1 lineages in which the ASP ORF is present.
METHODS
Study groups
Samples from serum and peripheral blood mononuclear
cells (PBMCs) from three healthy donors and six HIV-
infected individuals were used in this study. The subjects’
features and clinical information are summarized in Table 1.
Patient MP140 has been described elsewhere [18, 19]. Three
patients had detectable viraemia and were not receiving
ART at the time of sampling. Patients MP148 and MP140
were asymptomatic and naïve to therapy, whereas patient
MP135 was an AIDS patient who had gone repeatedly on
and off treatment and was untreated at the time of leuka-
pheresis. The other three patients were undergoing ART
and were aviraemic. These studies were approved by the
Institutional Review Board of the Centre Hospitalier Uni-
versitaire Vaudois (CHUV) and subjects gave written
informed consent.
Primary cells and sera
PBMCs from healthy donors were obtained by flebotomy.
In HIV-positive individuals, PBMCs were obtained by
Table 1. Patients’ features, clinical information and antiretroviral therapy status
Patient ID Age Sex Stage of HIV infection Clade Viral load
(copies ml 1)
CD4
Count
(cells µ 1)
ART status
MP135 44 M C3 B 1.6105 176 Untreated
MP140 23 M A2 B 3.6104 427 Naïve
MP148 37 M A1 B 2.0104 717 Naïve
MP069 42 M A1 B <20 1309 Treated
MP071 47 M C3 B <20 167 Treated
MP146 59 M C3 B <20 385 Treated
prior to alignment. As shown in the tree, the sequences from patients cluster with HXB2-LAI-IIIB-BRU, the reference sequence for
clade B, confirming that they are all of the B subtype.
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leukapheresis. Samples were stored in liquid nitrogen until
use. Sera were obtained by flebotomy using S-Monovette
(Sarstedt AG&Co., Nümbrecht, Germany) a few days
(<1week) before the leukapheresis. Serum was separated
from blood by centrifugation for 10min at 2000 r.p.m., ali-
quoted at 1ml/tube and stored at  80

C without further
manipulations. CD4+ T cells were isolated from PBMCs by
negative selection using the EasySep Human CD4+ TCell
Enrichment kit (Stemcell Technologies), following the man-
ufacturer’s instructions. Unfractionated PBMCs and puri-
fied CD4+ T cells were cultured in complete RPMI/10%
FCS/10 ngml 1 IL-2 at a concentration of 1106 cellsml 1
and plated in anti-CD3/CD28-coated (Becton Dickinson,
San Diego, CA, USA) 48-well plates at 1ml/well. Stimula-
tion was carried out for 4 to 5 days, depending on the
amount of cells available for each patient. Stimulated cells
were pelleted (1106/tube) and the pellets were stored at
 80

C until use. For the a-amanitin sensitivity assay,
CD4+ T cells were isolated and stimulated with anti-CD3/
CD28 as described above. At day 3 post-stimulation, the
cells were treated with increasing concentrations of a-ama-
nitin (5, 10, 20 and 100 µgml 1) (Sigma-Aldrich, St Louis,
MI, USA) with time points post-treatment collected at 4 h,
8 h and 24 h (day 4 post-stimulation). The IC50 for a-ama-
nitin was calculated using GraphPad Prism version 8.
In vitro infections
HIV-negative PBMCs were resuspended at 1106 cells ml 1
in complete RPMI/10% FBS, plated in six-well plates (3ml/
well) and treated with 50Uml 1 of IL-2 and 3 µgml 1 of
PHA. After 3 days, the cells were washed, resuspended in
complete RPMI and incubated with HIV-1HXB2 (37.6 ng/10
6
cells) in the presence of IL-2 and polybrene. The infection
was carried out for 4 days and monitored daily by flow cyto-
metric detection of intracellular p24.
Development of patient-specific RT-PCR primers
Given the high degree of variability of the envelope region
in which ASP is comprised, patient-specific primers had to
be developed in two steps, a HXB2-specific step and a
patient-specific step. In the HXB2-specific step, a primer
pair called PanASP was identified on the sequence of HXB2,
amplifying a fragment of 1094 bp, substantially exceeding
the ASP ORF both upstream and downstream (PanASPF –
ACCAAGCCTCCTACTATCATTATG; PanASPR – GCA-
CATTGTAACATTAGTAGAGCA). PanASP primers were
used to amplify proviral DNA from each patient. In the
patient-specific step, the proviral DNA PCR product was
sequenced (direct sequencing of amplification products)
and the sequence obtained was used to design primers inter-
nal to the PanASP fragment, which were specific for each
individual patient. Several oligoes, both sense and antisense,
were identified within the PanASP fragment, at various dis-
tances upstream and downstream from the ASP ORF. The
oligoes were tested in the patient’s proviral DNA in various
forward/reverse combinations and under various stringency
conditions. The pairs resulting in the best amplifications
(the longest fragment with the cleanest and most intense
signal) were selected for ASP detection.
Fig. 2. Detection of ASP RNA by RT-PCR in PBMCs of one healthy donor infected in vitro with HXB2. (a) Detection of ASP RNA using
standard RT-PCR. The ASP-specific band (141 bp) is clearly visible in the presence of the specific RT primer (lanes 1–3), although a
band of the same intensity is visible in samples reverse-transcribed in the absence of primer (lanes 4–6). (b) Detection of ASP RNA
using the modified Heist protocol. Reverse transcription of RNA from infected PBMCs in the presence of the biotinylated antisense
primer followed by purification of the cDNA leads to a clear band of the right molecular weight (lanes 1–3). In contrast, a weaker band
is still present in unpurified samples (lanes 4–6). No bands are visible in infected PBMCs reverse-transcribed in the absence of RT,
uninfected PBMCs or dH2O.
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Additional ASP oligoes amplifying shorter fragments
(<200 bp) were also designed based on the HXB2 sequence,
to be used for screening purposes (ASP141F: TGCACCAC
TCTTCTCTTTGC; ASP141R: TAACAACAATGGG
TCCGAGA; ASP171F: CCCTCATATCTCCTCCTCCA;
ASP171R: TAAAACAAATTATAAACATGTGGC). All pri-
mers were obtained from Integrated DNA Technologies
(San Jose, CA, USA).
Reverse transcription and PCR reactions
Total RNA was extracted using the RNeasy Mini kit (Qia-
gen, Hilden, Germany) and treated with the TURBO DNA-
free kit (Invitrogen, Thermo Fisher Scientific, Waltham,
MA, USA). RT reactions were carried out in a total volume
of 50 µl using SuperScript III Reverse Transcriptase (Invitro-
gen, Thermo Fisher Scientific, Waltham, MA, USA). Just
prior to RT, the RNA was fully denatured for 5min at 94

C
and quickly cooled down in iced water. For each reaction,
1–3 µg of RNA template, depending on the sample, was
used along with 2 pmol of a biotinylated version of the ASP-
specific antisense primer and 10mM of dNTPs. Reactions
were carried out for 1 h at 55

C prior to purification of the
ASP biotinylated cDNA by streptavidin-coated magnetic
beads (Invitrogen, Thermo Fisher Scientific, Waltham,
MA, USA).
Standard PCR reactions were performed in a total volume
of 50 µl, using the Platinum Taq DNA Polymerase High
Fidelity kit (Invitrogen, Thermo Fisher Scientific, Waltham,
MA, USA). PCR reactions were carried out over 35 cycles of
amplification. For analysis of genomic env, HIV genomic
RNA was extracted from 1ml serum using the QiAmp Viral
RNA Mini kit (Qiagen, Hilden, Germany). The reverse
transcriptase conditions, PCR and cloning manipulations
were the same as those used for ASP, with the exception of
the RT primer, which was antisense to env and not
biotinylated.
Cloning and sequencing
Amplified products were cloned into pCR 2.1 vector using
the TA cloning kit (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA). Clones bearing inserts were identified
by colony PCR and sequenced using the BigDye Terminator
v1.1 Cycle Sequencing kit (Applied Biosystems, Thermo
Fisher Scientific, Waltham, MA, USA) on an Applied Bio-
systems Automated Sequencer.
Nested real-time RT-PCR
Patient-specific qPCR primers and FAM and TAMRA
probes were synthesized by IDT-Integrated DNA Technolo-
gies (Coralville, IA, USA) and designed using the IDT Pri-
merQuest Tool available on the company’s website (https://
eu.idtdna.com/Primerquest/Home/Index). Total RNA was
extracted from purified CD4+ T cells, reverse-transcribed
with biotinylated primers and affinity-purified as described
above. Pre-amplification reactions of samples’ cDNA and
standard curve plasmid DNA were carried out in a total vol-
ume of 25 µl containing 1 µl of template, 0.1 µl Platinum
Taq DNA Polymerase High Fidelity (Invitrogen, Thermo
Fisher Scientific, Waltham, MA, USA), 0.2 µM primers,
0.2mM dNTPs and 1.5 µM to 2.5 µM Mg++ (depending on
the primers used). The reactions were carried out as follows:
initial denaturation for 2min at 95

C, amplification
through 18 cycles (30 s at 95

C, 30 s at 50

C, 40 s at 68

C)
and a 7min extension at 68

C. qPCR reactions were carried
out in a total volume of 20 µl containing 1 µl of pre-
Fig. 3. Detection of ASP RNA in PMBCs of one healthy donor infected in vitro with HXB2 by RT-PCR following RNA linearization. (a) The
ASP band is clearly visible in linearized RNA reverse-transcribed in the presence of the biotinylated specific primer followed by purifi-
cation of the cDNA (lanes 1–3). In contrast, no bands can be seen in purified cDNA from primer minus RT-PCR reactions (lanes 4–6),
although a band is clearly visible in the primer minus reaction in the absence of purification. (b) No bands can be detected in RNA
from infected PBMCs in RT minus controls, uninfected PBMCs or water. The positive control is ACH-2 gag RT-PCR.
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amplification PCR products diluted 1 : 5 in dH2O, 0.9 µM of
each qPCR primer and 0.25 µM of qPCR probe, using the
TaqMan Gene Expression Master Mix (Applied Biosystems,
Thermo Fisher Scientific, Waltham, MA, USA). The reac-
tion conditions were 10min at 95

C followed by 40 cycle of
amplification (15 s at 95

C and 1min at 60

C). For the
standard curve, pCR2.1 clones carrying patient-specific ASP
amplicons were used (see ‘Cloning and sequencing’ above).
Each plasmid was utilized at 3100–3106 copies to gener-
ate the PCR standard curve and the number of copies per
1 µl of cDNA was normalized to 1106 total CD4 cells. Data
were acquired using the Applied Biosystems StepOne Real-
Time PCR System (Applied Biosystems, Thermo Fisher Sci-
entific, Waltham, MA, USA) and analysed with the pro-
vided software.
Nested duplex RT-PCR for quantification of
a-amanitin inhibition
Total RNA was extracted as described above, and ASP RNA
levels were normalized to U6 snRNA (small nuclear RNA).
Duplex RT reactions were performed using 1 µg RNA tem-
plate and biotinylated reverse primers specific to ASP (Pan-
ASP R, see above) and U6 snRNA [20]. Following RT,
cDNAs were affinity-purified and resuspended in 10 µl of
dH2O. Pre-amplification of both ASP and U6 targets was
carried out in separate wells, adding 1 µl of duplex RT reac-
tion to a PCR mix containing 0.1 µl Platinum Taq DNA
Polymerase High Fidelity (Applied Biosystems, Thermo
Fisher Scientific, Waltham, MA, USA), 0.2 µM of each gene-
specific primer, 0.2mM each dNTPs, 2.5 µl 10 Taq buffer
and dH2O up to 25 µl for each sample. Pre-amplification
was performed using the following thermocycling condi-
tions: 2min at 95

C, 30 s at 95

C, 30 s at 55

C and 30 s at
68

C for a total of 14 cycles, followed by 7min final exten-
sion at 68

C. At the end of pre-amplification, 100 µl of
dH2O was added to each well (1:5 dilution). The qPCR was
performed using TaqMan Gene Expression Master Mix
(Applied Biosystems, Thermo Fisher Scientific, Waltham,
MA, USA) and primers/probes specific to ASP and U6.
Probes were labelled with FAM and TAMRA dyes at 5¢ and
3¢, respectively. All primers and probes were obtained from
IDT Integrated DNA Technologies (Coralville, IA, USA).
Each qPCR reaction was carried out in triplicate in a total
volume of 20 µl containing 1 µl of the diluted pre-amplifica-
tion product, 0.9 µM of each qPCR primer and 0.25 µM
probe. Reactions were carried out as follows: 10min at
95

C, followed by 15 s at 95

C and 1min at 60

C for a total
of 40 cycles. Data were acquired using the StepOnePlus
Real-Time PCR System (Applied Biosystems, Thermo
Fisher Scientific, Waltham, MA, USA) and analysed with
the provided software. The DDCTmethod was then used to
process these data to calculate relative gene expression for
the ASP RNA.
Nucleotide and aminoacid sequence analyses
Nucleotide sequence editing and alignments were per-
formed with Sequencher, BioEdit and CLUSTAL X software.
Phylogenetic analyses
Phylogenetic trees were inferred by the maximum-likelihood
method with 1000 bootstrap replicates using MEGA 7.0
software.
RESULTS
In this study we have developed a new approach to the
detection of antisense RNA, based on a modification of the
protocol proposed by Haist et al. [17]. Using this approach
we were able to identify ASP RNA in CD4+ T lymphocytes
Fig. 4. Quantitative analysis of ASP RNA expression in CD4+ T cells
isolated from three untreated, viraemic patients after stimulation with
anti-CD3/28. In patients MP135 and MP140, ASP RNA expression
peaks at day 4 post-stimulation, while in patient MP148, a peak in the
expression of ASP RNA can already be observed at day 2. The results
are expressed as ASP RNA copies/million CD4+ T cells. Each point in
the time course represents the mean value of triplicate PCR reactions.
Mancarella et al., Journal of General Virology 2019;100:863–876
868
Downloaded from www.microbiologyresearch.org by
IP:  130.223.52.104
On: Thu, 23 May 2019 06:48:54
isolated from five HIV-infected individuals. Three of our
subjects were not receiving therapy at the time of sampling
and had detectable viraemia, whereas the other two were
undergoing ART and were aviraemic (Table 1). ASP RNA
isolated from the three viraemic, untreated patients was
cloned and sequenced. Given the high genetic diversity that
characterizes env V4 and V5 in patients during the asymp-
tomatic stage at both inter- and intra-patient level [21–23],
the question arises of whether the products of ASP tran-
scription are also characterized by hypervariability, at least
to some degree. To address this point, and to assess whether
differences existed in terms of length variants between the
RNA transcript and the genomic sequence pools, the geno-
mic env region corresponding to ASP in the serum of each
patient was also cloned and sequenced. The phylogenetic
relations among the HIV isolates in the three viraemic
patients and their subtype assignment are shown Fig. 1. The
tree was inferred using the maximum-likelihood method
with 1000 bootstrap replicates using MEGA 7.0 software.
Sequences from both cells and serum were aligned with the
reference sequences of the HIV-1 M group subtypes, which
were obtained from the HIV sequence database (https://
www.hiv.lanl.gov/content/sequence/HIV/mainpage.html).
All sequences, both ASP and env, were in the env reading
frame. As shown in Fig. 1, the sequences from both ASP
and env all cluster with the HXB2-LAI-IIIB-BRU, confirm-
ing that they are all of the B subtype. In total, 56 nucleotide
sequences were obtained, 26 from CD4+ T lymphocytes
(ASP RNA transcripts) and 30 from serum (env genomic
RNA). The sequences are available in GenBank under acces-
sion numbers MH756691–756716 (RNA transcripts) and
MH756717–756746 (genomic RNA).
Development of a modified RT-PCR protocol for
antisense RNA detection
The experimental approach for the detection of ASP RNA
by RT-PCR was developed in PBMCs from one healthy
donor acutely infected in vitro with HXB2. In our first
attempt at detecting ASP RNA, we amplified a short frag-
ment (primer pair ASP141) using a standard antisense
primer (ASP141R) to perform RT. As shown in Fig. 2a, the
amplifications were successful, as we could clearly see a
band of the expected size (141 bp) in the HIV-1-infected
PBMCs (lanes 1–3). However, a band of the same molecular
weight and of the same intensity was also visible in RT reac-
tions performed without the RT primer (lanes 4–6). In
Fig. 5. Quantitative analysis of ASP RNA expression in CD4+ T cells isolated from two ART-treated, aviraemic patients after stimulation
with anti-CD3/28. In both patients, no ASP can be detected in unstimulated cells (day 0), with low levels of ASP RNA only becoming
detectable at day 2 (MP071) and day 4 (MP146) of the time course. The results are expressed as ASP RNA copies/million CD4+ T cells.
Each point in the time course represents the mean value of triplicate PCR reactions.
Mancarella et al., Journal of General Virology 2019;100:863–876
869
Downloaded from www.microbiologyresearch.org by
IP:  130.223.52.104
On: Thu, 23 May 2019 06:48:54
contrast, no bands were detected in either RT minus con-
trols or in uninfected PBMCs (lanes 7–8), indicating that
the bands in the RT primer minus controls were not due to
either leftover genomic DNA in the RNA or to cross-con-
tamination during PCR.
Our next step was to perform the RT using a biotinylated
version of the specific antisense primer, followed by purifi-
cation of the biotinylated cDNA, as described by Haist et al.
[17]. The results of this approach are shown in Fig. 2(b). A
clear band is present in RT reactions performed with the
biotinylated primer (lanes 1–3), whereas a band
characterized by markedly lower intensity is present in
primer minus controls (lanes 4–6). Although very encourag-
ing, these results were not yet satisfactory. In their paper,
Haist and coworkers also obtained some residual non-spe-
cific cDNA, which they eliminated by increasing the strin-
gency of the bead washes [17]. On our part, we wanted to
prevent the synthesis of non-specific products and only
amplify ASP RNA. We reasoned that, if indeed RNA sec-
ondary structures could prime the RT reaction, then the
answer was total linearization of the RNA prior to RT, com-
bined with biotinylation of the specific antisense primer and
Fig. 6. Quantitative analysis of ASP and env RNA in CD4+ T cells stimulated with anti-CD3/CD28 in one treated (MP146) and one
untreated (MP140) patient in the same qRT-PCR. (a) Linear graphic representation of ASP and env RNA in one patient in the absence of
therapy (MP140), showing that env expression occurs at levels that are much higher than those of ASP. (b) The same data as above
are represented on a logarithmic scale, showing that ASP and env share similar patterns of expression. (c) Linear graphic representa-
tion of ASP and env RNA in one aviraemic patient undergoing ART (MP146). ASP and env are both characterized by low levels of
expression, with env levels being higher than ASP levels and already becoming detectable at day 3 post-stimulation.
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Fig. 7. Inhibition of ASP expression in anti-CD3/CD28-stimulated CD4+ T cells from one untreated, viraemic patient (MP140) following
treatment with 20 µgml 1 a-amanitin. (a) Time-course of ASP expression in absence of a-amanitin, showing a sharp increase of the
relative ASP RNA levels between day 3 and day 4 post-stimulation. (b) If a-amanitin is added to the cultures at a concentration of 20 µg
Mancarella et al., Journal of General Virology 2019;100:863–876
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cDNA purification prior to PCR. The manufacturer’s proto-
col for SuperScript III Reverse Transcriptase, the enzyme we
were using, recommended denaturing RNA at 65

C. In
order to achieve total linearization of the RNA, we decided
to increase the denaturation temperature up to 94

C, fol-
lowed by immediate cooling of the tube in iced water. As
shown in Fig. 3(a), the linearization step still produces a
band of the right molecular weight (lanes 1–3), with total
elimination of non-specific amplification products (lanes 4–
6). In contrast, amplification of unpurified cDNA obtained
by RT of linearized RNA in the absence of the RT primer
still produces a band (lane 7). No signals were detected in
RT minus controls (Fig. 3b, lanes 1–3), uninfected PBMCs
or water (Fig. 3b, lanes 4 and 5). Sequencing of this band
directly from the PCR reaction confirmed that the amplified
product was indeed ASP (data not shown).
ASP transcripts have been detected in CD4+ T cells isolated
from viraemic, untreated HIV-infected subjects following
stimulation with anti-CD3/CD28. Having developed a reli-
able tool for antisense RNA detection, we were curious to
see whether we could also assess the presence of ASP RNA
in HIV-infected individuals. Our first attempts to detect
ASP transcripts were carried out in total PBMCs, either rest-
ing or stimulated with anti-CD3/CD28, from the three vir-
aemic subjects, MP135, MP140 and MP148. This approach,
however, did not produce any results (data not shown).
Attempts at detecting ASP RNA in purified, resting CD4+ T
cells using a panel of oligoes amplifying target sequences of
various sizes (ASP141, ASP171, PanASP, patient-specific
primers) were equally unsuccessful (data not shown). In
contrast, ASP detection in purified CD4+ T cells stimulated
with anti-CD3/CD28 produced a clear, specific signal in
each of the three patients tested (Figs S1–S3, available in the
online version of this article). The kinetics of expression
measured by qPCR show that in MP135 and MP140, the
ASP RNA increased over the first 4 days of stimulation,
peaking at day 4 (MP140), whereas in MP148 the peak had
already been reached at day 2 post-stimulation (Fig. 4).
Low levels of ASP RNA can be detected in treated
aviraemic patients after stimulation with anti-CD3/
CD28
Our next question was whether ASP could be detected in
treated subjects with undetectable viraemia. To this end, we
analysed ASP expression by qPCR in anti-CD3/CD28-stim-
ulated CD4+ T cells isolated from three additional patients,
MP069, MP071 and MP146, who were undergoing suppres-
sive therapy at the time of sampling. In patient MP069 we
could not visualize any ASP bands, regardless of the starting
template (proviral DNA, total RNA) and the primers (Pan-
ASP, ASP171, ASP141) used (data not shown). In the
absence of the amplification of proviral DNA, we could not
develop sequence-specific primers for this patient. As a
consequence, we cannot say whether the failure to amplify
ASP RNA was due to low similarity between the primer and
template sequences preventing amplification from occur-
ring, or to a real lack of ASP expression in this subject. In
the other two treated patients, MP071 and MP146, low lev-
els of ASP RNA could be detected at days 3 and 5 post-stim-
ulation, respectively (Fig. 5). The levels of expression in
these two patients were markedly lower than those observed
in patients who had detectable viraemia, corresponding to
10–15 copies/million CD4+ T cells.
Similar patterns of expression of ASP and env RNA could
be observed in one untreated, viraemic patient (patient
MP140). Next we wanted to know whether there were dif-
ferences in the kinetics of expression of ASP and env in the
same HIV-infected individual. To answer this question, we
analysed ASP and env RNA expression at different time
points following stimulation of cells with anti-CD3/CD28 in
one treated (MP146) and one untreated (MP140) patient in
the same qRT-PCR. The results of this experiment are
shown in Fig. 6 and Table S1. In patient MP140, both ASP
and env were detected, although with a profound difference
in transcription levels, with ASP quantified at 3.3104 cop-
ies µg 1 of total RNA and env at 1106 copies µg 1 (Fig. 6a
and Table S1). Interestingly, the curves of expression of the
two genes follow identical trends, as can be seen clearly if
the data are plotted on a logarithmic scale (Fig. 6b). In
MP146, which was treated and aviraemic, the expression of
both genes was very low, with env peaking at day 4 post-
stimulation with 5.5 copies µg 1 of total RNA and ASP
peaking at day 5 with 1.17 copies µg 1 (Fig. 6c and
Table S1). Given the low levels of ASP RNA and its delayed
expression, it is not possible to assess the similarities
between the two curves in this patient.
a-amanitin greatly reduces ASP RNA transcription
in one patient in the absence of therapy (patient
MP140)
Next we tested the sensitivity of ASP RNA to a-amanitin.
To this end, we stimulated CD4+ T cells isolated from
patient MP140 with anti-CD3/CD28, and added a-amani-
tin at increasing concentrations of 5, 10, 20 and 100 µg
ml 1 at day 3 post-stimulation, just prior to the peak in
ASP expression, which in this patient occurred at day 4
(Fig. 4). Cells were harvested at 4, 8 and 24 h post-treat-
ment and ASP RNA was quantified and normalized using
U6 snRNA, a housekeeping gene transcribed by RNAP III
[24] and thus not affected by our working concentrations
of a-amanitin. As shown in Fig. 7(a) and Table S2, the
addition of 20 µgml 1 a-amanitin at day 3 post anti-CD3/
CD28 stimulation strongly inhibited the expression of
ASP. This inhibitory effect could be fully appreciated at
day 4, the peak day for ASP expression in this patient.
Fig. 7(b) shows the kinetics of ASP inhibition at 4, 8 and
ml 1 at day 3 post-stimulation, the peak in ASP RNA expression at day 4 is inhibited. (c) Time course of ASP RNA inhibition showing
that ASP RNA levels decrease rapidly between 4 and 8 h after initiation of treatment.
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24 h post-treatment, with most of the inhibition occurring
between 4 and 8 h following the addition of a-amanitin at
20 µgml 1. When lower concentrations of a-amanitin
were used, corresponding to 5 or 10 µgml 1, there were no
significant inhibitory effects between time points at 5 and
10 µgml 1, although a trend towards decreased levels of
ASP RNA could already be observed between the 4 h time
points at 5 and 10 µgml 1 (Fig. S4). The IC50 for a-amani-
tin, determined by nonlinear regression using GraphPad
Prism version 8, was equal to 8.435 µgml 1 (Fig. 5).
Similar sequence variants can be detected in cells and serum
in untreated, viraemic patients during early HIV infection.
ASP RNA is synthetized from the complementary strand of
env spanning V4 and V5, two hypervariable regions that
have been shown to harbour marked length polymorphism
at intra-patient level [21–23]. As a consequence, it was pos-
sible that differences may exist between the pool of length
variants in ASP RNA from cells and in the genomic env
RNA pool. To answer this question, genomic env from
serum of the viraemic patients was also cloned and
sequenced. As shown in Table 2, the ASP length variants
that are dominant in cells are the same as those in genomic
env from serum. No ASP RNA was detected in patients’
serum (Fig. S6).
ASP ORFs can be of variable length due to different
types of stop codons
In HXB2, the ASP ORF is characterized by a TAG at posi-
tions 7375–7373, overlapping on the plus strand with the
codons for phenylalanine (F383) and tyrosine (Y384) of the
gp120 motif CGGEFFY, a highly conserved sequence
located at the junction C3/V4. Since this is the only stop
codon found in HXB2 ASP, and since it is located in a very
conserved region, we refer to it as ‘canonical’, meaning a
TAG stop codon with the same sequence and genomic loca-
tion as in HXB2. ASP ORFs of different length were identi-
fied in patients for the various clones. Table 2 summarizes
the length variants (i.e. the distance between the canonical
start and stop codons) of the ASP ORF in cells and serum.
In patient MP135, 18 sequences were obtained, 10 from
CD4 cells (ASP) and 8 from serum (env). In sequences from
cells, one clone had the full canonical ASP ORF, resulting in
a theoretical peptide of 192 amino acids (aa). Of the remain-
ing sequences, three clones had a TGA stop codon internal
to the canonical reading frame, resulting in a shorter ORF
of 115 aa, whereas the other six had a TGA stop codon
downstream from the canonical TAG, resulting in an ORF
of 212 aa, i.e. a little longer than the ORF found in HXB2.
No canonical ASP ORF was found in genomic RNA from
serum. In patient MP140, 17 clones were obtained, 8 from
cells (ASP) and 9 from serum (env). In both groups, about
half of the clones carried the canonical full coding region of
187 aa, whereas the other half carried a shorter variant of
104 aa. In patient MP148, a total of 21 sequences were
obtained, 8 from CD4 and 13 from serum. In all clones,
only a truncated ORF of 172 aa was found in both cells and
serum.
Non-canonical stop codons are located in variable
regions of gp120
Non-canonical stop sites mostly occurred within the canon-
ical ORF, giving rise to truncated ORFs, in regions that cor-
responded to gp120 V4 and V5. In patient MP135, 3/10
clones from CD4 RNA and 2/8 from serum RNA had a
TGA stop codon occurring at the amino terminus of the
corresponding env V5, giving rise to a truncated ORF of 115
aa. In addition, a longer ORF of 212 aa was also identified
in 6/10 clones from cells and 6/8 from serum. In these
clones, the TAG canonical stop disappeared due to a C=>A
mutation, leading to the substitution of phenylalanine F383
with leucine L383 and giving rise to the sequence CGGE-
FLY, which not only does not interrupt the env reading
frame, but is also quite conserved as an alternative to
CGGEFFY. Due to this mutation, the ASP ORF extended to
the C-terminus of C3, a region that has been shown to har-
bour variability to some degree at both inter- and intra-
patient level [23]. In patient MP140, four/eight clones in
cells and five/nine in serum were found to be carrying a
stop codon in V5. Finally, in patient MP148, only one trun-
cated ASP variant was identified, with a premature stop
codon occurring in V4 (Table 2).
The env fragment on the plus strand of non-
canonical ASP ORFs does not appear to be
defective
Regarding the plus strand sequence, a clearly defective env
in which the reading frame was interrupted by one or more
stop codons was only observed in three clones from cells
Table 2. Localization of ASP stop codons in gp120. Asterisks indicate the canonical stop codon at the junction C3/V4. Clones carrying the canonical
ORF are in bold
Patient ID No. of clones Region of stop codon ORF length (aa)
CD4 (ASP) Serum (env)
MP135 1/10 0/8 C3* 192
3/10 2/8 V5 115
6/10 6/8 C3 212
MP140 4/8 4/9 C3* 187
4/8 5/9 V5 104
MP148 8/8 13/13 V4 172
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and one clone from serum. In patient MP135, the only CD4
clone carrying the canonical ORF also carried a defective
env on the plus strand. In contrast, in patient MP140, the
clones carrying the canonical ASP also had a seemingly
functional env sequence on the plus strand, at least in the
fragment analysed in this study. In this patient, two clones
were found to be carrying the defective env, one in cells and
the other in serum. In both cases, the ASP sequence was
non-canonical with a stop site in V5. In patient MP148, a
defective env was also identified in one clone from CD4. In
all the other clones, the sequence of env appeared to be in-
frame, although we cannot exclude the occurrence of frame-
shifts and/or stop codons in regions other than ASP.
DISCUSSION
By using a modification of the protocol proposed by Haist
et al. [17], we detected and sequenced ASP RNA transcripts
in CD4+ T lymphocytes in three viraemic patients, who
were either naïve to therapy or untreated. We also detected
ASP expression in two additional patients who were under-
going ART and had undetectable viraemia, although at lev-
els that were lower than those found in untreated subjects.
In all patients, in order to detect ASP RNA, CD4+ T cells
had to be stimulated in vitro with anti-CD3/CD28, since no
ASP RNA could be detected in resting cells. In a previous
study, Zapata et al. proposed that ASP is a regulatory RNA
involved in HIV latency [14]. In their paper, they reported
low levels (10–30 copies of RNA/106CD4+ T cells) of ASP
expression in resting CD4+ T cells from three patients
under suppressive ART for over 24months. We also
detected ASP expression in treated patients at similar levels
to those described by Zapata and coworkers; in our case,
however, CD4+ T lymphocytes had to be stimulated for 2
(MP071) to 4 (MP146) days in order to see ASP expression,
since no signal could be detected in resting cells. This dis-
crepancy could be explained by the fact that they used a reg-
ular RT-PCR protocol that does not involve any RNA
denaturation step. We have shown that in the absence of a
rigorous denaturation, non-specific synthesis of sense RNA
(i.e. env) may occur to some extent, which could explain the
low signal they detected in their samples. We also show that
the expression of ASP and env share similar profiles over
time, which is in contrast with the proposed role of ASP as a
regulator of latency [14]. In fact, if that were the case, an
inverse correlation between env (sense) and ASP (antisense)
transcription should be expected [2]. The finding that in
untreated, viraemic patients, the transcription levels of env
are over 2 logs more abundant than those of ASP fully
agrees with the data reported by Laverdure et al. [25], indi-
cating that in activated primary CD4+ T cells infected in
vitro, 3¢LTR activity is very low, up to 1000-fold lower than
the 5¢ LTR sense transcription. Our data clearly show that
infected CD4+ T cells can express ASP regardless of the
stage of the disease, at least in those patients in which the
ASP ORF is present. We also show that cells need to be
stimulated in order to produce ASP RNA and that even cells
from ART-treated patients are able to express ASP,
although to a lesser extent than cells from untreated ones.
In addition, our data represent the first nucleotide sequen-
ces of ASP transcripts in infected subjects.
The ASP ORF is known to be quite conserved among iso-
lates of subtype B [10], and in fact we found it in all of the
analysed clones. However, the length of this ORF was vari-
able, due to a shift of the stop codon upstream or down-
stream from its canonical position in HXB2, leading to ASP
ORFs that were shorter or longer than the HXB2 ORF. In
HXB2, the ASP stop site is a TAG spanning the codons for
F383 and Y384 of the motif CGGEFFY, at the junction C3/
V4 on the plus strand. Cassan et al. [10] defined this kind of
stop codon as being imposed by the coding of Env. Indeed,
this motif of gp120 is highly conserved and contains several
functional and structural sites involved in Env–host biologi-
cal signalling, such as part of the coreceptor-binding site
outside V3 (F383) and part of the recombinant human
monoclonal antibody IgG1b12 epitope (Y384) [26]. The
degree of conservation of this motif is so high that it can be
found unchanged not only across HIV-1 subtypes and
groups, but also in other species of lentiviruses, such as sim-
ian immunodeficiency virus (SIV). In cells, although the
ASP ORF was present in all the clones, the canonical (i.e. as
found in HXB2) TAG site could only be observed in two
patients, MP135(in 12.5% of the clones) and MP140 (in
exactly 50% of the clones). Given the very low number of
sequences analysed in this study, these values can be consid-
ered to be quite relevant. Interestingly, no canonical ASP
ORF was found in MP148, who was also the earliest of our
patients and had been infected for less than a year. Our
inability to recover the canonical ORF in this patient does
not necessarily imply its absence early during infection,
since this could have been due to its frequency being lower
than our detection limit, as in the case of patient MP135, in
which the canonical ASP ORF was recovered from cells but
not from serum.
In addition to the stop codons imposed by the coding of
env, Cassan et al. [10] also observed stop codons due to
mutations on the plus strand that can appear/disappear
without modifying env, seemingly corresponding to those
that we observed in V5, V4 and the C-terminus of C3 on
the plus strand. The obvious question at this point is
whether ORFs carrying alternative (i.e. non-canonical) stop
codons may still encode for a functional ASP RNA or pro-
tein. It would be logical to think that functional gene prod-
ucts are more likely to be encoded by ORFs that are
relatively constant, including the position of the stop codon,
which must be located in a region that is conserved enough
to yield transcription/translation products sharing the same
structural features, as in the case of the HXB2 canonical
TAG. In this perspective, the actual occurrence of the ASP
canonical stop codon in such a highly conserved region
appears to be the product of a complex process of selection,
whereby the transcription of a functional ASP may occur
regardless of the high variability of its env template. How-
ever, the translation of novel ORFs created by the
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mutational gain or loss of start and stop codons has been
proposed as one of the mechanisms underlying the evolu-
tion of gene overlaps [27]. Thus, the canonical ORF as
found in HXB2 could be considered to be the actual func-
tional ASP ORF, whereas the frequent occurrence of alter-
native stop sites in highly variable regions could be
explained by the ASP ORF being in the evolution process
[10] through the constant generation of random-length
mutants.
ASP and env are located in the same region of the HIV-1
genome, overlapping one another in opposite orientations.
As a matter of fact, overlapping genes are a common feature
of viruses, in which they typically code for accessory pro-
teins involved in viral pathogenicity or spread [28, 29].
Overlapping proteins have been shown to have a sequence
composition that is globally biased towards amino acids
with a high codon degeneracy, such as arginine, leucine, or
serine [28, 30], in order to compensate for mutations that
may occur on the ‘ancestral’ or ‘overprinted’ protein to
which they overlap. In addition, it has been shown that
most overlapping proteins have been created anew and that
most proteins created anew are orphans, meaning that they
are restricted to just one species or genus [28]. Interestingly,
not only are leucine and serine among the most abundant
amino acids in the sequence of ASP [1, 11, 12], but also no
clear links have been found between ASP and any other
known three-dimensional structures in the Protein Data-
bank (PDB) (A. V. Kajava, personal communication), sug-
gesting that ASP may indeed be a protein-coding orphan
gene, restricted solely to the M group of HIV-1. Sensitivity
to a-amanitin is additional evidence for the existence of an
ASP gene product. RNA polymerases (RNAP) are classified
based on their differential sensitivity to a-amanitin. In ani-
mal cells, RNAP II is generally very sensitive, showing 50%
inhibition at 2–20 µgml 1 of a-amanitin [31–33], whereas
RNAP I and RNAP III are resistant to higher concentra-
tions, up to 1mgml 1 for RNAP I, and 100–150 µg ml for
RNAP III. The fact that ASP expression is already inhibited
by a-amanitin at a concentration of 20 µgml 1 indicates
that it is likely associated with RNAP II, the enzyme respon-
sible for mRNA synthesis during the transcription of pro-
tein-coding genes.
Further studies are under way to characterize the full-length
transcript of ASP and assess its subcellular distribution in
infected subjects The discovery of a new HIV antigen would
represent an important step in our understanding of HIV
pathogenesis and perhaps open up new perspectives in the
development of novel anti-HIV drugs and vaccines.
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